TNV262

TNV262 is an investigational **small molecule** inhibitor of the **NLRP3 inflammasome** being developed by **Tenvie Therapeutics**. It is described as a **fully CNS-penetrant** program designed to modulate innate immune-driven chronic inflammation, with development focused on **cardiometabolic diseases** including **obesity** and **cardiovascular disease**, as well as **multiple sclerosis**. As of April 2026, TNV262 had entered **Phase 1** clinical testing in a first-in-human single- and multiple-ascending-dose study in healthy volunteers and persons with obesity, with evaluation of safety, tolerability, pharmacokinetics, and exploratory pharmacodynamics. Preclinical disclosures indicate complete CNS penetrance and a favorable safety profile.